Continue to site >
Trending ETFs

Name

As of 07/11/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$156.45

$968 M

0.00%

0.81%

Vitals

YTD Return

15.8%

1 yr return

33.7%

3 Yr Avg Return

1.8%

5 Yr Avg Return

7.9%

Net Assets

$968 M

Holdings in Top 10

40.9%

52 WEEK LOW AND HIGH

$153.0
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 0.81%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 47.30%

Redemption Fee N/A


Min Investment

Standard (Taxable)

$1,000,000

IRA

N/A


Fund Classification

Fund Type

Open End Mutual Fund


Name

As of 07/11/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$156.45

$968 M

0.00%

0.81%

FRBRX - Profile

Distributions

  • YTD Total Return 15.8%
  • 3 Yr Annualized Total Return 1.8%
  • 5 Yr Annualized Total Return 7.9%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.25%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    FRANKLIN BIOTECHNOLOGY DISCOVERY FUND
  • Fund Family Name
    Franklin Templeton Investments
  • Inception Date
    Sep 13, 2013
  • Shares Outstanding
    84661
  • Share Class
    R6
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Evan McCulloch

FRBRX - Performance

Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
YTD 15.8% -22.8% 31.2% 5.56%
1 Yr 33.7% -31.4% 41.8% 1.23%
3 Yr 1.8%* -33.4% 14.3% 44.52%
5 Yr 7.9%* -5.1% 17.3% 66.91%
10 Yr 6.9%* -0.1% 13.2% 74.77%

* Annualized

Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
2023 18.9% -12.6% 19.0% 1.23%
2022 -12.7% -53.9% 3.2% 49.68%
2021 -27.7% -39.6% 24.2% 96.13%
2020 14.7% -13.6% 178.2% 43.05%
2019 24.2% 3.8% 63.8% 29.63%

Total Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
YTD 15.8% -22.8% 31.2% 5.56%
1 Yr 33.7% -31.4% 41.8% 1.23%
3 Yr 1.8%* -33.4% 14.3% 44.52%
5 Yr 7.9%* -5.1% 17.3% 66.91%
10 Yr 6.9%* -0.1% 13.2% 74.77%

* Annualized

Total Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
2023 18.9% -12.6% 19.0% 1.85%
2022 -12.3% -53.9% 3.7% 62.58%
2021 -17.4% -33.9% 26.0% 93.55%
2020 30.3% -0.7% 180.6% 29.80%
2019 35.3% 4.6% 63.8% 8.89%

NAV & Total Return History


FRBRX - Holdings

Concentration Analysis

FRBRX Category Low Category High FRBRX % Rank
Net Assets 968 M 7.41 M 47.2 B 48.77%
Number of Holdings 101 25 420 29.01%
Net Assets in Top 10 358 M 3.14 M 22.7 B 53.70%
Weighting of Top 10 40.92% 17.8% 78.7% 75.31%

Top 10 Holdings

  1. Amgen, Inc. 7.08%
  2. Regeneron Pharmaceuticals, Inc. 6.34%
  3. Vertex Pharmaceuticals, Inc. 5.34%
  4. Ascendis Pharma A/S 4.03%
  5. AstraZeneca plc 3.44%
  6. Biogen, Inc. 3.18%
  7. Gilead Sciences, Inc. 3.01%
  8. Institutional Fiduciary Trust - Money Market Portfolio 2.97%
  9. Intra-Cellular Therapies, Inc. 2.92%
  10. Neurocrine Biosciences, Inc. 2.62%

Asset Allocation

Weighting Return Low Return High FRBRX % Rank
Stocks
96.75% 89.34% 106.13% 76.54%
Cash
3.77% 0.00% 34.44% 32.10%
Convertible Bonds
0.37% 0.00% 0.37% 1.91%
Preferred Stocks
0.31% 0.00% 7.86% 25.93%
Other
0.00% -22.99% 23.31% 72.22%
Bonds
0.00% 0.00% 12.39% 75.31%

Stock Sector Breakdown

Weighting Return Low Return High FRBRX % Rank
Healthcare
99.75% 59.26% 100.00% 58.60%
Basic Materials
0.25% 0.00% 7.16% 28.03%
Utilities
0.00% 0.00% 0.00% 66.88%
Technology
0.00% 0.00% 22.69% 68.79%
Real Estate
0.00% 0.00% 5.89% 69.43%
Industrials
0.00% 0.00% 7.02% 68.79%
Financial Services
0.00% 0.00% 1.60% 78.34%
Energy
0.00% 0.00% 0.00% 66.88%
Communication Services
0.00% 0.00% 9.11% 70.06%
Consumer Defense
0.00% 0.00% 25.73% 71.34%
Consumer Cyclical
0.00% 0.00% 1.92% 69.43%

Stock Geographic Breakdown

Weighting Return Low Return High FRBRX % Rank
US
96.50% 69.36% 104.41% 38.89%
Non US
0.25% 0.00% 27.72% 61.73%

FRBRX - Expenses

Operational Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.81% 0.08% 4.28% 65.43%
Management Fee 0.61% 0.03% 1.25% 25.31%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.15% 0.03% 0.25% 64.86%

Sales Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 47.30% 0.00% 238.00% 48.55%

FRBRX - Distributions

Dividend Yield Analysis

FRBRX Category Low Category High FRBRX % Rank
Dividend Yield 0.00% 0.00% 6.24% 78.40%

Dividend Distribution Analysis

FRBRX Category Low Category High Category Mod
Dividend Distribution Frequency Annual Annual Quarterly Annual

Net Income Ratio Analysis

FRBRX Category Low Category High FRBRX % Rank
Net Income Ratio -0.25% -2.54% 1.85% 52.90%

Capital Gain Distribution Analysis

FRBRX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

Distributions History

View More +

FRBRX - Fund Manager Analysis

Managers

Evan McCulloch


Start Date

Tenure

Tenure Rank

Sep 15, 1997

24.72

24.7%

Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.

Wendy Lam


Start Date

Tenure

Tenure Rank

Sep 01, 2018

3.75

3.8%

Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co. Ms. Lam has a Ph.D degree.

Akiva Felt


Start Date

Tenure

Tenure Rank

Jan 27, 2020

2.34

2.3%

Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.87 0.25